Novartis announced positive news for patients with metastatic breast cancer. New data showed Kisqali (ribociclib), in combination with the chemotherapy drug fulvestrant, added nearly 16 months of survival benefit to the lives of patients compared to fulvestrant alone.
Astellas Pharma Inc. announced topline results from the Phase 3 SKYLIGHT 4 clinical trial investigating the long-term safety of fezolinetant, an investigational oral, nonhormonal compound being studied for the treatment of moderate to severe vasomotor symptoms associated with menopause (VMS) which will support future regulatory filing submissions.
Astellas Pharma studied the potential of fezolinetant, a selective neurokinin-3 receptor (NK3R) antagonist, against hot flashes in a series of double-blinded and placebo-controlled trials.
San Diego-based Ligand Pharmaceuticals is acquiring San Diego-based Pfenex for a total deal transaction of up to $516 million.
With a $425 million upfront payment, Bayer bolstered the company’s women’s healthcare pipeline with the acquisition of U.K.-based KaNDy Therapeutics and an investigational treatment for menopause.
The European Commission granted marketing authorization to Amgen and UCB for Evenity (romosozumab) for treating severe osteoporosis in postmenopausal women at high risk of fracture.
For Breast Cancer Awareness Month, BioSpace gathered examples of recent breakthroughs in breast cancer treatment.
Novartis’ Phase III MONALEESA-3 clinical trial of Kisqali (ribociclib) hit the key secondary endpoint, overall survival.
